Retro-AAV Capsid Engineering for Selective D1-MSN Retrograde Targeting
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for Parkinson's disease lack specificity due to the wide distribution of dopamine receptors, leading to inefficiencies in targeting striatal D1 medium spiny neurons, which are chronically suppressed in the disorder.
Innovation Solution
Development of chimeric AAV viruses with variant capsid polypeptides promoting retrograde transport and heterologous genes operatively coupled to regulatory elements, along with designer receptors activated by designer drugs (DREADD), to selectively manipulate D1-MSN activity.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If conventional AAV vectors are used for gene therapy delivery, then general tissue transduction is achieved, but selective targeting of striatal D1 medium spiny neurons is insufficient
Solution Approach 1:
The patent applies local quality by engineering capsid proteins with specific mutations (e.g., AAV2-I246R, AAV8-K263R) that confer retrograde transport capability. This localized modification of the capsid structure enables selective targeting of D1 medium spiny neurons projecting to the substantia nigra, while other neuronal populations remain unaffected. The mutated capsids exhibit enhanced affinity for specific neuronal transport mechanisms, achieving cell-type-specific delivery.
Solution Approach 2:
The patent utilizes parameter changes by modifying physical-chemical properties of the AAV capsid through amino acid substitutions. These mutations alter the capsid's interaction with cellular receptors and endosomal escape mechanisms, enabling retrograde axonal transport. The changed parameters include capsid surface charge, hydrophobicity, and conformational stability, which collectively enhance neuronal uptake and retrograde transport efficiency.
2Measurement precision
If systemic dopamine receptor agonists are administered, then dopamine receptor activation is achieved, but specificity to PD-affected circuitry is lost
Solution Approach 1:
The patent applies segmentation by dividing the therapeutic approach into two distinct components: (1) selective delivery of the DREADD receptor to specific D1 medium spiny neurons using retrograde AAV vectors, and (2) systemic administration of the inert ligand clozapine. This segmentation allows the active therapeutic element (DREADD) to be localized precisely in target neurons while the ligand remains inert systemically, achieving circuit-specific modulation without widespread dopamine receptor activation.
Solution Approach 2:
The patent introduces an intermediary system consisting of the DREADD receptor (hM3Dq or rM3Ds) that mediates between the inert ligand clozapine and the neuronal output. The DREADD acts as a selective intermediary that converts systemic clozapine administration into localized neuronal activation only in D1 medium spiny neurons where the receptor is expressed, thereby achieving specificity without requiring specific drug distribution.
3Reliability
If retrograde AAV vectors are engineered with capsid mutations, then neuronal retrograde transport is enhanced, but viral vector complexity increases
Solution Approach 1:
The patent applies taking out by isolating and characterizing the specific capsid mutations responsible for retrograde transport capability. By identifying critical residues (e.g., I246R in AAV2, K263R in AAV8), the invention extracts the essential functional elements from complex capsid structures. This allows for simplified vector design where only the critical mutated capsid gene is modified, while other vector components remain standard, reducing overall complexity.
Data Source
AI summary
The present invention provides for retro adeno-associated virus (retro-AAV) virions comprising a variant capsid polypeptide, wherein the variant capsid polypeptide comprises one or more alterations that promote retrograde transport of the retro-AAV by a neuron, and a nucleic acid comprising a heterologous gene of interest operatively coupled to a GPR88 and/or a R9P1 regulatory region.